Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JBPOS0604
- Development stage
- Preclinical
- Lead developer
- Bio-Pharm Solutions
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
JBPOS0604 is a novel small molecule anticonvulsant candidate being developed by Bio-Pharm Solutions. Currently in the preclinical stage, the compound has been evaluated through the National Institute of Neurological Disorders and Stroke (NINDS) Anticonvulsant Screening Program (ASP), often referred to as the "Red Book." JBPOS0604 is being investigated for the treatment of various seizure disorders, including pediatric orphan indications such as Infantile Spasms (IS) and Lennox-Gastaut Syndrome (LGS), as well as for applications in pain management. It belongs to a class of functionalized amino acid derivatives designed to provide broad-spectrum anti-seizure activity with a favorable safety profile.
Beyond the preview
Go deeper on JBPOS0604.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JBPOS0604.